Neuphoria Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Valuation Ratios
P/S Ratio0.85
P/B Ratio0.70
Price/Tangible Book2.40
Price/FCF172.83
Price/OCF172.83
Enterprise Value Ratios
Profitability & Returns
Return on Equity (ROE)-0.02%-0.78%-0.71%-0.42%-0.29%
Return on Assets (ROA)-0.02%-0.40%-0.37%-0.18%-0.14%
Return on Capital Employed (ROCE)-0.03%-0.75%-0.83%-0.28%-0.20%
Leverage & Solvency Ratios
Debt/Equity0.010.020.020.010.02
Debt/FCF1.93
Liquidity Ratios
Current Ratio3.563.454.8712.4613.10
Quick Ratio3.373.334.5812.0212.55
Efficiency Ratios
Asset Turnover0.560.100.02
Yield & Distribution Ratios
Earnings Yield-0.03%
FCF Yield0.01%
Buyback Yield-0.95%1.00%-0.09%-0.74%-0.43%